文献速递前列腺癌

年龄与前列腺癌对前列腺体积、PSA及PSA密度的影响

The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density.
PubMed 文献 · BJU Int · 2026-02-23

这项单中心回顾性横断面研究纳入2512名男性,其中760名无症状无病男性,1752名接受前列腺癌诊断路径的患者,采用MRI测量全腺体前列腺体积。研究发现无症状男性前列腺体积随年龄非线性增长,PSA随年龄增长,而PSA密度阈值0.15 ng/mL²可跨年龄应用。

要点

  • 无症状男性前列腺体积随年龄非线性增长,48.9岁后变化率增加。
  • PSA随年龄增长,有和无临床显著前列腺癌患者中均呈正相关。
  • PSA密度阈值0.15 ng/mL²可在所有年龄范围应用以区分临床显著前列腺癌。

核心结论

  • 无症状男性前列腺体积随年龄非线性变化,支持年龄相关PSA阈值,但静态PSA密度阈值0.15 ng/mL²可跨所有年龄范围应用。

研究设计与样本

  • 单中心回顾性横断面研究,纳入2512名男性,包括760名无症状无病男性和1752名接受前列腺癌诊断路径的患者,使用MRI测量全腺体前列腺体积,并采用机器学习流程建模。

主要发现

  • 无症状男性(中位前列腺体积25.4 mL)各年龄组平均前列腺体积随年龄非线性增加,从18岁时的18.7 mL(年增长0.10 mL)至89岁时的41.3 mL(年增长0.68 mL),变化率从48.9岁起增加。
  • 有和无临床显著前列腺癌患者中PSA与年龄均呈显著正相关(r²=0.09 vs 0.13),PSA平均每年增加0.17 ng/mL,临床显著前列腺癌患者PSA水平持续更高。
  • PSA密度在临床显著前列腺癌患者中随年龄呈显著线性增加,但在无临床显著前列腺癌患者中所有年龄均持续较低(0.10-0.11 ng/mL²),允许以>0.15 ng/mL²为阈值进行区分。

关键数值与推荐

  • PSA密度阈值>0.15 ng/mL²可用于区分临床显著前列腺癌,适用于所有年龄范围。
  • 年龄相关PSA阈值得到支持。

临床怎么用

  • 临床可采用静态PSA密度阈值0.15 ng/mL²跨年龄评估前列腺癌风险,并考虑年龄对PSA的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess prostate volume (PV) changes with age in symptomatic and asymptomatic men with and without clinically significant prostate cancer (csPCa). In symptomatic patients, we additionally analysed the effect of age and csPCa on PSA and PSA-density (PSA-D) and compared these to current National Institute for Health and Care Excellence (NICE) recommended PSA age-range thresholds. Patients and Methods This single-centre retrospective cross-sectional study included 2512 men: 760 asymptomatic, disease-free men and 1752 patients referred on a PCa diagnostic pathway. Magnetic resonance imaging-derived whole-gland PV was recorded for all patients. A machine-learning pipeline with k-fold cross validation modelled relationships between PV and age. RESULTS: In asymptomatic men (median PV 25.4 mL), the mean PV per age-group increased non-linearly with age, from 18.7 mL at an increase of 0.10 mL/year aged 18 years, to 41.3 mL at 0.68 mL/year aged 89 years, with increased rate of change from the age of 48.9 years. Significant positive relationships were shown between PSA and age in patients with and without csPCa (r2 = 0.09 vs 0.13, respectively), with PSA increasing by mean 0.17 ng/mL/year across groups. Patients with csPCa had consistently higher PSA levels. PSA-D showed significant age-related linear increases in patients with csPCa but remained consistently lower in those without csPCa at all ages (0.10-0.11 ng/mL2), allowing differentiation at a threshold of >0.15 ng/mL2. CONCLUSION: In asymptomatic men, PV changed non-linearly with age. Age-related PSA thresholds are supported; however, a static PSA-D threshold of 0.15 ng/mL2 can be applied across all age ranges.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Rusbridge J, Caglic I, Thavaraja L, et al. The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density. BJU Int. 2026. PMID: 41730523. doi:10.1111/bju.70169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。